Oral Vimpat Approved for Use in Pediatric Patients with Partial-Onset Seizures

 

The FDA approved a label extension for Vimpat (lacosamide, UCB) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older. The expanded indication is based on the principle of extrapolation of its efficacy data from adults to children, and is supported by safety and pharmacokinetics data collected in children, according to the company. Data suggest that adverse reactions to oral Vimpat in pediatric patients are similar to those seen in adult patients.

Vimpat injection has not been established in pediatric patients and is only  indicated for the treatment of partial-onset seizures only in patients 17 years of age and older.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC